Introducere. Cercetările recente au demonstrat că microambianţa tumorală joacă un rol esenţial în progresia cancerului mamar, iar limfocitele sunt cruciale în răspunsul imun anti-tumoral. Scopul lucrării. Determinarea conţinutului de limfocite T CD3+ în carcinomul mamar (CM) asociat cu diabetul zaharat de tip 2 (DZ2). Material şi metode. 58 de carcinoame mamare ductal invazive de tip NST (Institutul Oncologic, 2021-2022) au fost investigate imunohistochimic (bufer cu pH înalt, microundă 900W, 95°C, 20 minute, anticorp primar CD3/F7.2.38, Dako/20min/l:100, Dako Autostainer Link 48, Zeiss Axiolmager 2.0 cu Axio- Cam Mrc5). În 29 cazuri CM a fost asociat cu DZ2. WINSTAT 2012.1 a fost utilizat pentru analiza statistică (corelaţie după Spearman (rs), X±SD, mediana (Me), t-Student). Rezultate. În CM, conţinutul limfocitelor CD3+ peritumorale (CD3pt) (33.6±16.3, Me = 29) a corelat statistic semnificativ cu activitatea mitotică a neoplasmului (rs = 0.35, p = 0.03) şi vârsta pacientelor (rs = -0.45, p = 0.01), fără asocieri semnificative cu CD3+ intratumorale (CD3it) (rs = 0.16, p = 0.21, 16.7±14.8, Me = 14.5, t = -6.54, p = 0.001). În CM asociat cu DZ2, CD3it (18.6±15.8, Me = 19) au prezentat corelaţii semnificative doar cu vârsta pacientelor (rs = 0.47, p = 0.01), fără asocieri concludente cu conţinutul CD3pt (35.7±18.9, Me = 31, t = -2.04, p = 0.04). Conţinutul de limfocite nu a fost diferit statistic la compararea CM cu CM+DZ2. Concluzii. În carcinomul mamar, conţinutul limfocitelor T cu sediu intra- şi peritumoral este diferit. DZ2 asociat CM modifică nu conţinutul de limfocite CD3+, ci asocierile acestora cu alţi marked ai progresiei tumorale.
Introduction. Recent research has demonstrated that the tumor microenvironment plays an essential role in the progression of breast cancer, and lymphocytes are crucial in the antitumor immune response. The aim of the work. To determine the content of CD3+ T lymphocytes in breast carcinoma (CM) associated with type 2 diabetes mellitus (T2DM). Material and methods. 58 invasive ductal breast carcinomas of the NST type (Oncological Institute, 2021- 2022) were investigated immunohistochemically (high pH buffer, microwave 900W, 95°C, 20 minutes, primary antibody CD3/F7.2.38, Dako/20min/l:100, Dako Autostainer Link 48, Zeiss Axiolmager 2.0 with AxioCam Mrc5). In 29 cases CM was associated with T2DM. WINSTAT 2012.1 was used for statistical analysis (Spearman’s correlation (rs), X±SD, median (Me), t-Student). Results. In CM, the content of peritumoral CD3+ lymphocytes (CD3pt) (33.6±16.3, Me = 29) correlated statistically significant with the mitotic activity of the neoplasm (rs = 0.35, p = 0.03) and the age of the patients (rs = -0.45, p = 0.01), without significant associations with intratumoral CD3+ (CD3it) (rs = 0.16, p = 0.21, 16.7±14.8, Me = 14.5, t = -6.54, p = 0.001). In CM associated with T2DM, CD3it (18.6±15.8, Me = 19) presented significant correlations only with patients’ age (rs = 0.47, p = 0.01), without conclusive associations with CD3pt content (35.7±18.9, Me = 31, t = -2.04, p = 0.04). Lymphocyte content was not statistically different after comparing CM with CM+DZ2. Conclusions. The content of intra- and peritumoral T-lymphocytes in breast carcinoma is different. CM-associated T2DM influences not CD3+ lymphocytes content but their associations with other markers of tumor progression.